×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
JAGX – jaguar health, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
JAGX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/16
09:32 am
jagx
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression [Yahoo! Finance]
Low
Report
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression [Yahoo! Finance]
3/11
09:03 am
jagx
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts [Yahoo! Finance]
High
Report
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts [Yahoo! Finance]
3/9
09:22 am
jagx
Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants [Yahoo! Finance]
High
Report
Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants [Yahoo! Finance]
1/24
05:09 am
jagx
Jaguar Animal Health (NASDAQ:JAGX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Jaguar Animal Health (NASDAQ:JAGX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
1/22
09:15 am
jagx
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi [Yahoo! Finance]
Medium
Report
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi [Yahoo! Finance]
1/6
09:12 am
jagx
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication [Yahoo! Finance]
Medium
Report
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/13
05:00 pm
jagx
Form PRE 14A Jaguar Health, Inc. For: Apr 20
Low
Report
Form PRE 14A Jaguar Health, Inc. For: Apr 20
3/12
03:04 pm
jagx
Form 4 Jaguar Health, Inc. For: Dec 11 Filed by: MICEK JOHN
Low
Report
Form 4 Jaguar Health, Inc. For: Dec 11 Filed by: MICEK JOHN
3/9
09:05 am
jagx
Form 8-K Jaguar Health, Inc. For: Mar 06
High
Report
Form 8-K Jaguar Health, Inc. For: Mar 06
3/6
04:16 pm
jagx
Form 8-K Jaguar Health, Inc. For: Mar 05
High
Report
Form 8-K Jaguar Health, Inc. For: Mar 05
3/3
09:06 am
jagx
Form 8-K Jaguar Health, Inc. For: Mar 02
High
Report
Form 8-K Jaguar Health, Inc. For: Mar 02
2/18
09:02 am
jagx
Form 8-K Jaguar Health, Inc. For: Feb 18
Medium
Report
Form 8-K Jaguar Health, Inc. For: Feb 18
2/10
02:12 pm
jagx
Form SCHEDULE 13G/A Jaguar Health, Inc. Filed by: Lincoln Alternative Strategies LLC
Medium
Report
Form SCHEDULE 13G/A Jaguar Health, Inc. Filed by: Lincoln Alternative Strategies LLC
1/23
04:15 pm
jagx
Form 8-K Jaguar Health, Inc. For: Jan 16
Low
Report
Form 8-K Jaguar Health, Inc. For: Jan 16
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/11
Jaguar Health Subsidiary Receiving Preclinical Services Funded by the National Institute of Allergy and Infectious Diseases in Support of Development of Lechlemer Drug Product Candidate for Cholera Indication
35.0%
10/30 Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc. 28.6%
11/12 Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates 25.7%
12/31 Jaguar Health Inc (NASDAQ: JAGX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 17.8%
9/30 Jaguar Health Subsidiary Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Application 12.0%
9/12 Jaguar Health Inc (NASDAQ: JAGX) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating on the stock. 10.8%
8/20 Form 3 Jaguar Health, Inc. For: Aug 13 Filed by: Lizak Carol R. 10.3%
6/24 Jaguar Health Regains Compliance with All Applicable Nasdaq Stock Market Listing Standards 9.5%
9/16 Jaguar Health's Mytesi Drug Product Now Approved for Sale in Puerto Rico 8.3%
12/26 Form 8-K Jaguar Health, Inc. For: Dec 20 6.9%
10/30 Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc. 28.6%
11/12 Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates 25.7%
12/31 Jaguar Health Inc (NASDAQ: JAGX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 17.8%
9/30 Jaguar Health Subsidiary Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Application 12.0%
9/12 Jaguar Health Inc (NASDAQ: JAGX) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating on the stock. 10.8%
8/20 Form 3 Jaguar Health, Inc. For: Aug 13 Filed by: Lizak Carol R. 10.3%
6/24 Jaguar Health Regains Compliance with All Applicable Nasdaq Stock Market Listing Standards 9.5%
9/16 Jaguar Health's Mytesi Drug Product Now Approved for Sale in Puerto Rico 8.3%
12/26 Form 8-K Jaguar Health, Inc. For: Dec 20 6.9%
TOP News Decliners
11/14
Jaguar Health Inc (NASDAQ: JAGX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating.
-28.8%
4/16 Form 8-K Jaguar Health, Inc. For: Apr 15 -22.1%
8/14 Form 10-Q Jaguar Health, Inc. For: Jun 30 -20.9%
6/6 Jaguar Health, Inc. Announces 1-for-70 Reverse Stock Split -19.0%
3/23 Form 8-K Jaguar Health, Inc. For: Mar 21 -19.0%
7/5 Form FWP Jaguar Health, Inc. Filed by: Jaguar Health, Inc. -15.1%
9/24 Form 8-K Jaguar Health, Inc. For: Sep 24 -12.9%
5/11 Jaguar Health readies $10M equity offering [Seeking Alpha] -12.6%
7/15 Form S-1/A Jaguar Health, Inc. -12.4%
10/1 Jaguar Health Files Final Canalevia (Crofelemer) Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs -12.2%
4/16 Form 8-K Jaguar Health, Inc. For: Apr 15 -22.1%
8/14 Form 10-Q Jaguar Health, Inc. For: Jun 30 -20.9%
6/6 Jaguar Health, Inc. Announces 1-for-70 Reverse Stock Split -19.0%
3/23 Form 8-K Jaguar Health, Inc. For: Mar 21 -19.0%
7/5 Form FWP Jaguar Health, Inc. Filed by: Jaguar Health, Inc. -15.1%
9/24 Form 8-K Jaguar Health, Inc. For: Sep 24 -12.9%
5/11 Jaguar Health readies $10M equity offering [Seeking Alpha] -12.6%
7/15 Form S-1/A Jaguar Health, Inc. -12.4%
10/1 Jaguar Health Files Final Canalevia (Crofelemer) Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs -12.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: